

## Purpose & Background

The COVID -19 pandemic provided a unique opportunity for many nurse-driven initiatives and collaborations. With the advent of COVID-19 treatments, the staff of Adirondack Health, implementing evidence-based practice, developed policies and protocols for monoclonal antibody infusion for out-patients diagnosed with mild-moderate COVID-19 and at risk for severe progression of the disease and/or hospitalization.

## Objectives

- Objective 1:** Develop a policy and procedure for monoclonal antibody infusion for the treatment of COVID-19
- Objective 2:** Mitigate the disease progression in patients diagnosed with mild- moderate COVID -19
- Objective 3:** Keep patients alive

## Plan Do Check Act

**P:** A review of literature and best practices was conducted in concert with pharmacy and medical staff. Suitable locations for infusion administration and staff to provide treatment were identified.

**D:** Utilizing resources provided by the NYSDOH, the CDC and the manufacturer of Regen-Cov®, an initial policy and procedure along with accompanying documentation and forms were developed.

**C:** Processes and procedures were continually reviewed and continue to be reviewed to achieve the most efficient and best practice.

**A:** The finalized policy and procedure are in place and can be easily adapted and revised as treatments or locations change.



ICU RNs review orders before beginning an infusion.



Chief Nursing Officer David Mader prepares an infusion for a resident of Mercy Living Center.

## Domains of Quality Addressed


- Safe** Protocols were developed and revised to maintain the safety of both staff and patients.
- Timely** Infusions became available as COVID infections from the Delta variant peaked in 2021. As new variants became prominent, we were able to quickly modify protocols.
- Efficient** Infusions were usually scheduled within 24 hours of receiving the provider order for treatment.
- Effective** No patient was transferred to a higher level of care or required hospitalization for further treatment of COVID-19.
- Equitable** Treatment was available to all patients who met the medical criteria.
- Person-centered** As is the goal of all care provided by AH staff, patients' values and health goals were considered and respected.



A nurse comforts a SNF resident during her infusion.

## Outcomes Achieved

### Outpatient Monoclonal Antibody Infusions



## Conclusions & Lessons Learned

Being flexible and adaptable were key to the success of this initiative. Recognizing that written processes may need to be adjusted or revised to increase safety and efficiency and listening without ego to the frontline staff administering treatment, led to the development of a protocol that impacted and continues to impact the health of our community.

## References

Eli Lilly and Company. (May 2021) fact sheet for health care providers emergency use authorization (eua) of bamlanivimab and etesevimab. [www.fda.gov/media/145802/download](https://www.fda.gov/media/145802/download)

Eli Lilly and Company (February 2022) Fact sheet for healthcare providers: emergency use authorization for Bebtelovimab. <https://www.fda.gov/media/156152/download>

GlaxoSmithKline LLC (March 2022) Fact sheet for healthcare providers emergency use authorization (eua) of sotrovimab. [www.fda.gov/media/149534/download](https://www.fda.gov/media/149534/download)

Omnicare. (n.d.). *Skills Checklist 30: Administration of Monoclonal Antibody*. CVS Health company. [https://hsc.unm.edu/echo/\\_docs/hhs-covid/hhs-miniseries/6-ltc.pdf](https://hsc.unm.edu/echo/_docs/hhs-covid/hhs-miniseries/6-ltc.pdf)

Regeneron. (September 2021). Fact sheet for health care providers emergency use authorization (EUA) of REGEN-COV™ (casivirimab and imdevimab) for coronavirus disease 2019 (COVID19) <https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf>

Sakata, T., Brunisholz, K. D., Andersen, C., Davie, D., Srivastava, R., & Webb, B. J. (2021). The MAb Squad: Delivering Covid-19 Monoclonal Antibody Therapy Across a Large Geographic Region. *Nejm Catalyst Innovations in Care Delivery*, 2(9), 10.1056/CAT.21.0154. <https://doi.org/10.1056/CAT.21.0154>



Submitted on behalf of the Patient Care Services division and the staff who helped deliver this potentially life-saving treatment.

#### Contact Information

David Mader, BSN, RN, CCRN-K, NE-BC  
Chief Nursing Officer, Adirondack Health  
dmader@adirondackhealth.org 518-897-2255

Carrie Reardon, BSN, RN  
AVP Patient Care Services, Adirondack Health  
creardo@adirondackhealth.org 518-897-2507

Jake Singer, PharmD, RPh  
Director of Pharmacy, Adirondack Health  
jsinger@adirondackhealth.org 518-897-2319

Kristin Finn, BSN, RNC  
Director of Staff Development, Adirondack Health  
kfinn@adirondackhealth.org 518-897-2209